

Nuformix plc
("Nuformix" or "the Company")

Appointment of Broker

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, is pleased to announce the appointment of Beaufort Securities Limited as the Company's broker.

Follow Nuformix on Vox Markets: follow at www.voxmarkets.co.uk/company/NFX
and www.nuformix.com

ENDS

Enquiries:

Nuformix plc +44 (0)1223 423667

Dan Gooding, Chief Executive
Officer

Beaufort Securities Limited +44 (0)20 7382 8300
(Joint Broker)

Jon Belliss

Gable Communications Ltd +44 (0)20 7193 7463

John Bick / Justine James

About Nuformix plc www.nuformix.com

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix' risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

Nuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

Nuformix was established in Cambridge in 2008 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.